Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (January 2020)
16 slides from Arbutus Biopharma's investor presentation, Jan 13, 2020
Slide 1: Singularly Focused on HBV
Singularly Focused on HBV January 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this pur
Slide 3: Investment Highlights
Investment Highlights Singular therapeutic focus - curing chronic Hepatitis B Virus (HBV) Infection Team With Significant Goal of Broad Strong Antiviral Unmet Medical Functional HBV Financial Expertise & Need in HBV Cure Portfolio Position Proven Track Record Global HBV prevalence Delivered through
Slide 4: Proven Leadership Team
Proven Leadership Team William H. Collier Michael J. Sofia, PhD Gaston Picchio, PhD Successful track records President and CEO Chief Scientific Officer Chief Development Officer in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine,
Slide 5: HBV Lifecycle Illustrates Key Points for Intervention
HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1 –Nucleoside Analogue 2 –Capsid Inhibitor 3 –RNAi & RNA Destabilizer 2 3 1 2 NASDAQ: ABUS www.arbutusbio.com
Slide 6: Keys to Therapeutic Success
1 Reduce/Suppress Reduce/Suppress Keys to Viral DNA 2 Viral Antigens Therapeutic Block Replication Block HBsAg . NA . RNAi . Capsid Inhibitor . RNA Destabilizer Success . RNAi . RNA Destabilizer Reduce cccDNA Pool . Capsid Inhibitor Suppress HBV DNA and viral antigens Leading to an Reawaken host HBV
Slide 7: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Lead IND Enabling Healthy Subjects HBV Subjects Phase II Optimization HBsAg Reduction RNAi AB-729 AB-452 HBV RNA Destabilizers 2nd Gen HBV DNA Suppression Capsid Inhibitor AB-836 Immune Reawakening PD-L1 1st gen NASDAQ: ABUS www.arbutusbio.com 7
Slide 8: AB-729 RNAi
AB-729 RNAi Single trigger RNAi agent targeting all HBV transcripts Therapeutic Inhibits HBV replication and lowers all HBV antigens Pan-genotypic activity across HBV genotypes Duration of HBsAg reduction supports once per month dosing Proprietary GalNAc-conjugate delivery technology provides Demons
Slide 9: AB-729 Single Dose Response
AB-729 Single Dose Response 4 AB-729 Saline 3 1 mg/kg In Vivo Single & 3 mg/kg 2 9 mg/kg Multiple Dose 1 (LOG IU/mL)(LOG Serum HBsAg Response & 0 SC dose LLOQ Duration -1 0 2 4 6 8 10 Study Week Strong dose response 5 in AAV mouse model AB-729 Multiple Dose Response Stepwise reduction of HBsAg 4 Sal
Slide 10: AB-729 Phase 1a/b Study Design
AB-729 Phase 1a/b Part 1: Part 2: Part 3: Study Design Blinded SAD in SAD in HBV Subjects 3 and 6 Month Multiple- Healthy Volunteers dose in HBV Subjects Starting dose 60 mg Starting dose selected Dose selected from part 2 Preliminary results from Part 1 anticipated late Q1 2020 6 subjects per cohor
Slide 11: AB-452 - A Small Molecule HBV RNA Destabilizer
AB-452 - A Small Molecule HBV RNA Destabilizer Class I RNA DMSO NA Capsid Class II Destabilizer Control ETV GLS-4 Capsid AB-452 Concentration in nM 0 0 1000 1000 1000 1000 1000 1000 70 70 pgRNA 1 Total sRNA RNA 28S Ribosomal RNA Control AB-452 causes a reduction in HBV RNA, 18S Ribosomal RNA Control
Slide 12: AB-452 - A Small Molecule HBV RNA Destabilizer
AB-452 - A Small Molecule HBV RNA Destabilizer Dose-dependent reduction in HBsAg correlates with reduction of liver HBV RNA 125 100 100 Untreated Vehicle 75 0.1 mg/kg 10 0.3 mg/kg 50 (% Baseline) Serum HBsAg 1 mg/kg Liver HBV RNA (Day 7, %Untreated)(Day 7, 25 1 0 0 1 2 3 4 5 6 7 Study Day PO BID for
Slide 13: AB-452 and Next Gen RNA Destabilizer Program
AB-452 and Next Gen RNA Destabilizer Program . Multiple evaluations of AB-452 nearing completion . On track for AB-452 go/no go decision in early 2020 . Active program evaluating next generation small molecules NASDAQ: ABUS www.arbutusbio.com 13
Slide 14: AB-836 Capsid Inhibitor
AB-836 Capsid . Novel chemical series differentiated from AB-506 and other competitor Inhibitor compounds in the Class II capsid inhibitor space . Leverages a novel binding site within the core protein dimer-dimer interface IND enabling . Improved intrinsic potency with EC50 < 10 nM studies ongoing
Slide 15: AB-836: A Next Generation Capsid Inhibitor
AB-836: A Next Generation Capsid Inhibitor cccDNA Formation / Human Serum HBV DNA / 1o Mechanism 2o Mechanism Shift HBV infected HBV infected Core I105T HBV infected HepDE19 (FC in EC in 40% Compound PHH HepG2-NTCP-C4 Mutation HepG2-NTCP-C4 50 (EC50 μM) Human Serum) (EC50 μM) (EC50 μM) (EC50 µM) (HB
Slide 16: Key Objectives for 2020 Supported by Cash Runway Into Mid-2021
Key Objectives for 2020 Supported by Cash Runway Into Mid-2021 1Q 2020 2H 2020 AB-452 AB-729 AB-729 AB-836 Go/no go Preliminary Multiple dose Complete IND decision Phase 1a/1b data enabling data, single studies dose NASDAQ: ABUS www.arbutusbio.com 16
Arbutus Biopharma — Investor Presentation (January 2020) on 6ix